D-1046-2019 Class II Terminated
FDA drug recall D-1046-2019 was initiated by AVKARE Inc. on Mar 5, 2019 and is designated Class II. Reason for recall: CGMP Deviations: presence of an impurity, N-Methylnitrosobutyric acid (NMBA) was identified The recall status is terminated (terminated Dec 7, 2020).
Recall details
- Product Type
- Drugs
- Report Date
- Mar 27, 2019
- Initiation Date
- Mar 5, 2019
- Termination Date
- Dec 7, 2020
- Voluntary/Mandated
- Voluntary: Firm initiated
Product description
Losartan Potassium and Hydrochlorothiazide Tablets, USP 100 mg/12.5 mg 50 Tablets (5x10) Unit Dose boxes, Rx Only Manufactured for: AvKARE Inc. Pulaski, TN 38478 --- NDC 50268-514-15
Reason for recall
CGMP Deviations: presence of an impurity, N-Methylnitrosobutyric acid (NMBA) was identified
Distribution pattern
Nationwide.
Code information
Lot: 19326 Exp. 03/31/2019
Source
- Dataset
- openFDA drug recall enforcement reports
- FDA record
- This recall in openFDA (JSON)
- Enforcement Report
- Search FDA's Enforcement Report for D-1046-2019
- openFDA file date
- Nov 10, 2026
- Loaded by RegDataLab
- Nov 11, 2026